Biotech with exciting gene therapy climbs 50% in a week – The Pharma Letter (registration)
The Pharma Letter (registration) |
Biotech with exciting gene therapy climbs 50% in a week
The Pharma Letter (registration) US gene therapy developer Abeona Therapeutics (Nasdaq: ABEO) is set to start trading on Monday with a share price worth around $13.60, more than 50% higher than it was a week ago. It comes amid excitement at the potential of Abeona’s EB-101 gene … |
Salon |
If you could edit your child’s genes, would you?
Salon In early August, Nature reported that an international group of scientists used CRISPR–Cas9 gene editing technology to correct a mutation in the DNA in human embryos. The embryos in question were not implanted, but the mere fact that this experiment … UC researchers use new method to identify gene enhancersXinhua Molecular scissors fix disease-causing flaw in human embryosScience News for Students |
|
Editas Medicine, Inc. (NASDAQ:EDIT) Traded Significantly Above Its …
Finance Daily Shares last traded at $20.59 significantly above $18.27, the stock’s 50 day moving average and a tad higher than the 200 day moving average of $19.21. The 50 … |
Scottish Daily Record |
Family hope to raise £160k for groundbreaking stem cell treatment for daughter, Ivy, who suffers from cerebral palsy
Scottish Daily Record A connection through family led to meeting Dr Joanne Kurtzberg, who is awaiting approval from the US Food and Drug Administration for stem cell treatment with donor cells on cerebral palsy patients. Kurtzberg has agreed to accept Ivy on to the trial if … |